Expertise in “intensified perfusion” cell culture technology, enabling our highly trained scientists to convert fed-batch processes to our continuous biomanufacturing platform.

The result is maximizing the yield of the client’s product while producing biologics of the highest product quality and significantly lowering COGS for commercial production

Staff is highly skilled in the use of Design of Experiment methodology to streamline process development and enhance output and timelines.

Capitol Biologics is on the cutting edge of developing a high throughput proprietary CHO host cell line for our client’s needs, along with a continuous downstream bioprocess utilizing single-use technologies.